CITY, Month Day, 2025-06-15 23:27:00
Opioid-Induced Constipation: A Closer Look
Certain opioid medications carry a higher risk of severe constipation, highlighting the need for tailored pain management.
- Morphine, oxycodone, and fentanyl are linked to a higher risk of constipation.
- Tramadol may offer a lower risk of severe constipation compared to codeine.
- Higher daily opioid doses (over 50 MME) considerably increase constipation risk.
Are you dealing with constipation while taking opioids? A recent study reveals that specific opioid medications and higher doses can increase the risk of this uncomfortable side affect. Researchers found that patients administered morphine, oxycodone, or fentanyl faced a greater chance of experiencing constipation compared to those on codeine.
Opioids, a class of drugs often used to manage pain, are known for their potential to cause constipation and other gastrointestinal issues. These medications bind to receptors not onyl in the brain and spinal cord but also in the gut, leading to reduced bowel movements and increased fluid absorption. This can result in hard stools that are difficult to pass[[8]. The extent to which different opioids affect these receptors can vary based on the specific drug’s properties. Tramadol, for instance, has a different mechanism of action. It also partially inhibits the reuptake of serotonin and norepinephrine[[17]. This difference might explain why tramadol was associated with a lower risk of severe constipation compared to codeine in the study.
buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor[[18], which might potentially be associated with the lower incidence rate of events compared to codeine and the statistically non-significant lower adjusted HR.Codeine,often considered a less potent opioid[[19], did not show the lowest risk of this outcome.
Why This Matters
Previous studies assessing the risk of constipation among different opioids have produced conflicting results. this inconsistency stems partly from the lack of a universally accepted definition for opioid-induced constipation and potential underreporting when relying on diagnostic codes in electronic health records (EHRs).
One study, comparing codeine and tramadol, found no significant differences in constipation risk using primary care EHRs from Catalonia in Spain[[20]. However, the outcome definition in this study relied on ICD-10 codes, likely underrepresenting the true extent of constipation. For instance, the incidence rate of any constipation event for codeine using ICD-10 codes was 6.41 per 1000 person-years[[20]. In contrast, the study’s rate for severe constipation on codeine was 8.61 per 1000 person-days, which is higher and more aligned with patient self-reports, suggesting underreporting when using health codes alone. Another study of 14,491 patients with osteoarthritis found that patients starting tramadol had lower rates of constipation and other opioid-related issues compared to those on other opioids[[21], which supports the current study. Neither study considered the effect of daily dosage on outcomes, though.
The Role of Dosage
Higher doses of opioids, measured in morphine milligram equivalents (MME) per day, are associated with a range of adverse events. Healthcare providers globally recommend caution and careful monitoring for patients on doses between 50 and 120 MME/day[[1, 15,16]. This study revealed that the risk of severe constipation significantly increased in patients on 50 MME/day or more, emphasizing the importance of carefully managing opioid use based on individual patient needs[[22].
Did you know? The risk of severe constipation increases significantly for patients taking 50 MME/day or more. Talk to your doctor about managing your dosage and potential side effects.
Patients on higher doses might require more careful monitoring and proactive strategies to prevent or manage constipation. The data show that it can be challenging to collect dose data, especially when dealing with “as needed” and reg
Beyond Medication: Proactive Constipation Management
While the choice of opioid and dosage are critical, effective constipation management involves more than just switching medications. A comprehensive approach that combines lifestyle adjustments and, when necessary, medical interventions can significantly improve patient outcomes.
One of the first steps is increasing dietary fiber intake. Fiber adds bulk to the stool, making it easier to pass. Patients should aim for approximately 25-30 grams of fiber per day, which can be achieved through a diet rich in fruits, vegetables, and whole grains. Adequate hydration is also crucial, as fluids help soften stools. Regular exercise promotes gut motility, further aiding in preventing constipation. Even moderate physical activity, like brisk walking, can make a difference.
When lifestyle changes aren’t enough,healthcare providers often recommend over-the-counter or prescription medications. Stool softeners, such as docusate sodium, help draw water into the stool and make them easier to pass. Osmotic laxatives, like polyethylene glycol (MiraLAX), work by drawing water into the colon. stimulant laxatives, such as bisacodyl or senna, stimulate bowel contractions but should be used cautiously and for short periods, as they can lead to dependency. Peripherally acting μ-opioid receptor antagonists (PAMORAs) represent a newer class of medications that target the opioid receptors in the gut to counteract the constipating effects of opioids without affecting pain relief. These medications, like methylnaltrexone and naloxegol, can be especially effective for patients experiencing opioid-induced constipation.
Patient education is paramount. Healthcare professionals should discuss the risk of constipation with patients before starting opioid therapy, emphasizing the importance of recognizing symptoms early. Patients should be provided with clear instructions on lifestyle modifications and the proper use of medications. Regular follow-up appointments allow for monitoring of bowel habits and adjustments to the treatment plan as needed. Open communication between patients and their providers is essential for optimizing pain management and minimizing the adverse effects of opioid use.
Table of Contents
